New Marketing Authorization Application (MAA) ... - CLL Support
New Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib
You need to be a member of this community to see this post.
Read more about...
1 Reply
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
Can anyone confirm if Ibrutinib is now available on prescription in the UK?
I just received an email from a friend to suggest it is available. I’m to start 6 months of BR...
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Bloodwise news
Blood cancer drugs kept on the Cancer Drugs Fund
We're delighted to announce that NHS England have...
Related Posts
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'- FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
A new kid on the block? Nemtabrutinib
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)- Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
